To date, there have been accumulating evidences that ATF is a powerful drug carrier for anti-cancer drug delivery (Todhunter et al., 2004; Takei et al., 2005; Hall & Vallera, 2006; Sun et al., 2008; Provenzano et al., 2016; Su et al., 2016), with a dissociation constant of 0.2 nM to the cell surface uPAR (Li et al., 2014). The gene discussed is PLAU; the disease is cancer.